RDT | Jotup

Reveal Technology Has Been Awarded a $749K Small Business Innovation Research (SBIR) Phase II With Air Force Research Laboratory Center for Rapid Innovation

Retrieved on:

목요일, 11월 2, 2023

3D, Intelligence, AFRL, Farstream, AFWERX, United States Department of the Air Force, SBIR, Air Force Research Laboratory, Research, RDT, Artificial intelligence, Department of Defence, Air force, 3D printing

BOZEMAN, Mont., Nov. 2, 2023 /PRNewswire/ -- Reveal Technology, Inc. (Reveal) has been awarded a $749K Small Business Innovation Research (SBIR) Phase II with Air Force Research Laboratory for research, development, testing, and evaluation (RDT&E) of the Farsight platform.

Key Points:

BOZEMAN, Mont., Nov. 2, 2023 /PRNewswire/ -- Reveal Technology, Inc. (Reveal) has been awarded a $749K Small Business Innovation Research (SBIR) Phase II with Air Force Research Laboratory for research, development, testing, and evaluation (RDT&E) of the Farsight platform.
Reveal will work alongside the United States Air Force, to optimize Farsight to perform autonomous airfield assessments.
The assessments will be performed utilizing Farsight generated 3D models overlaid with intelligent analytics.
"Reveal understands the importance of autonomous capabilities in the next fight and looks forward to seeing its impact on joint all-domain operations."

AI Diagnostic Platform Company Noul, unveils the result of Malaria study in Ethiopia and Ghana

Retrieved on:

월요일, 10월 23, 2023

In the study, the scientists compared the sensitivity and specificity of the qPCR with those of miLab™, field microscopy, and Rapid Diagnostic Test (RDT) respectively.

Key Points:

In the study, the scientists compared the sensitivity and specificity of the qPCR with those of miLab™, field microscopy, and Rapid Diagnostic Test (RDT) respectively.
Diagnosis of P. falciparum infections included cases with hrp2/hrp3 gene deletion with renders parasites 'invisible' to common rapid diagnostic tests.
Also, the diagnostic results of miLab™ in P. falciparum infected patients with hrp2/hrp3 gene deletion have been released.
This new study in Ethiopia and Ghana confirmed the clinical performance of miLab™ as a reliable new tool in the diagnosis of P. falciparum and P. vivax malaria.

National Armaments Consortium Elects Dave Turovsky Chair of its Executive Committee

Retrieved on:

수요일, 9월 27, 2023

SUMMERVILLE, S.C., Sept. 27, 2023 /PRNewswire/ -- The National Armaments Consortium (NAC) today announced the election of Dave Turovsky as its next Executive Committee (ExCom) Chair. He will assume this role on October 1, 2023.

Key Points:

SUMMERVILLE, S.C., Sept. 27, 2023 /PRNewswire/ -- The National Armaments Consortium (NAC) today announced the election of Dave Turovsky as its next Executive Committee (ExCom) Chair.
"Today marks an important milestone for the National Armaments Consortium as we welcome Dave Turovsky as our new Executive Committee Chair, and we introduce a dynamic group of defense industry professionals to our ExCom," said NAC Executive Director Charlie Zisette.
He is an OTA specialist and has served as a member of the NAC Executive Committee from 2018 to 2023.
NAC also expressed its deepest appreciation to former Executive Committee Chair James F. Miller and ExCom member Dan Hartman for their exceptional service on the NAC Executive Committee.

Mangoceuticals Brand MangoRx Announced as Raindance Film Festival’s Headline Sponsor

Retrieved on:

목요일, 9월 14, 2023

Heart, Partnership, Venice Film Festival, Raindance Film Festival, Marketing, Marriage, Hope, Oxytocin, RDT, RNZ National, Chemistry, Erectile dysfunction, ED, Mental health, Film industry, Raindance

Dallas, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” today announced it will be the headline sponsor for the thirty-first edition of the Raindance Film Festival, the UK’s leading indie film festival. Raindance returns to the heart of London’s West End from October 25 through November 4, 2023.

Key Points:

As the headline sponsor of the 2023 festival, MangoRx will have a strong presence throughout the festival’s various programming including an orange carpet takeover at all celebrity carpet events, a MangoRx 60-second short film competition, hosted panels from Mango’s’ team of experts, and even a signature MangoRx themed cocktail.
Through its partnership with Raindance, MangoRx increases awareness around sexual health in film and helps remove the stigma around erectile dysfunction.
MangoRx will host a new 60-second short film competition, with short filmmakers challenged to focus on mental health and its connection to ED.
I’m also excited that Raindance is challenging short filmmakers to focus on mental health and ED with our MangoRx 60-second short film competition.”
“Our partnership with Raindance Film Festival brings attention to issues surrounding men’s physical and mental health through award-winning storytelling,” said MangoRx CEO Jacob Cohen.

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Retrieved on:

수요일, 9월 13, 2023

These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .

Key Points:

These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .
The data show the ability of Molecular Partners to substantially increase tumor uptake of RDT candidates through an adjustment of systemic half-life, achieved by binding to the common blood protein serum albumin.
With today’s data we show that tuning of half-life can substantially impact the tumor uptake of our Radio DARPins,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.
Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.

Mangoceuticals Launches New High-Production Quality Ad Providing Fresh Insight into its Proprietary Mango Erectile Dysfunction Pill Formula

Retrieved on:

수요일, 8월 30, 2023

Arginine, Marketing, Taboo, RDT, Mango, Entrepreneurship, Erectile dysfunction, Perfume, Tadalafil, Oxytocin

Differences between the newest Mango formulation (with Sildenafil) and the Company’s flagship Mango formulation (with Tadalafil) involve the main active ingredient and the lasting effects of each at effective levels in the bloodstream.

Key Points:

Differences between the newest Mango formulation (with Sildenafil) and the Company’s flagship Mango formulation (with Tadalafil) involve the main active ingredient and the lasting effects of each at effective levels in the bloodstream.
Sildenafil is the active ingredient in Viagra™ while Tadalafil is the active ingredient in Cialis™.
Sildenafil lasts up to 4 hours, while Tadalafil may last up to 36 hours.
Otherwise, both formulations are compounded with Oxytocin (aka, the “cuddle chemical”, helping you connect with your partner during intimacy) and L-Arginine (a proven blood flow enhancer).

Mangoceuticals Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve

Retrieved on:

수요일, 8월 16, 2023

Sildenafil, Arginine, Half-life, Marketing, Oxytocin, RDT, Tablet, Investment, Entrepreneurship, Erectile dysfunction, Fine chemical, Tadalafil

Interested consumers can now proceed through the Company’s telemedicine platform and select either a Sildenafil-based Mango or the Company’s original Tadalafil-based Mango ED product, which leverages the active ingredient found in Cialis™.

Key Points:

Interested consumers can now proceed through the Company’s telemedicine platform and select either a Sildenafil-based Mango or the Company’s original Tadalafil-based Mango ED product, which leverages the active ingredient found in Cialis™.
Both the Sildenafil and Tadalafil-based Mango ED products are compounded with Oxytocin and L-Arginine in a tasty Mango-flavored, rapid dissolve tablet (RDT) and individually packaged in a master pack of six tablets per package.
For example, Tadalafil has been proven to last longer than Sildenafil due to a half-life more than four times as long.
Cohen added, “Perhaps the most important point here is that we are standing on the shoulders of billions of dollars of prior marketing spend.

Amentum and Beast Code Partner to Deliver Digital Engineering Technologies

Retrieved on:

화요일, 8월 8, 2023

Amentum and Beast Code announce the companies have entered into a strategic agreement to bring together premier global engineering solutions with cutting edge technology to help accelerate the federal government’s modernization initiatives in digital engineering.

Key Points:

Amentum and Beast Code announce the companies have entered into a strategic agreement to bring together premier global engineering solutions with cutting edge technology to help accelerate the federal government’s modernization initiatives in digital engineering.
Beast Code’s software aggregates data from multiple disparate sources and presents the information intuitively through an immersive three-dimensional digital twin.
Beast Code’s technology complements Amentum’s engineering end-to-end lifecycle solutions in digital engineering, C5ISR, research and development, infrastructure, platform modernization, logistics, training, data analytics and cybersecurity.
Driven by Amentum’s longstanding, trusted relationship with the U.S. government supporting the most complex missions, the partnership will leverage Beast Code’s digital twin software to accelerate adoption of digital technologies across defense, civilian, and intelligence community markets.

Mangoceuticals, Inc. Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Fox Business, Bloomberg TV, and Newsmax TV

Retrieved on:

수요일, 7월 12, 2023

The interview was filmed at the Nasdaq MarketSite Studio and will air on Fox Business Network, Bloomberg TV (as a sponsored program), and Newsmax TV (through its syndicated and sponsored networks) as follows:

Key Points:

The interview was filmed at the Nasdaq MarketSite Studio and will air on Fox Business Network, Bloomberg TV (as a sponsored program), and Newsmax TV (through its syndicated and sponsored networks) as follows:
July 22 at 3:30 p.m.
ET on Newsmax TV
July 24 at 10:30 p.m. PT on Fox Business
August 5 at 6 p.m.
Cohen concludes by pointing to the Company’s overall mission: to promote men’s performance in all areas and aspects of life.
Through its network of syndication, FMW programming reaches an estimated 540 million homes across US and international markets.

Rapid Dose Therapeutics Reports Fiscal Year 2023 Financial Results

Retrieved on:

수요일, 6월 28, 2023

Biotechnology, Medical Devices, Health, Pharmaceutical, Medical Supplies, Nicotine, File, Lidocaine, USD, RDT, Pharmaceutical industry

The initial product, Lidocaine for the dental applications, was tested during the third and fourth quarters of the fiscal year with a launch date of May 1, 2023;

Key Points:

The initial product, Lidocaine for the dental applications, was tested during the third and fourth quarters of the fiscal year with a launch date of May 1, 2023;
RDT was contracted to formulate and develop an oral thin film strip containing nicotine as the active ingredient.
The pre-commercialization project continues throughout the current fiscal year ending February 28, 2024.
The project generated USD$90,000 in consulting services revenue during the fourth quarter of the 2023 fiscal year;
The Company continued to experience regulatory approval hurdles and delays for product applications in Europe, USA, and Canada.
Subsequent to the year end, approvals have been obtained for the distribution of nutraceutical and cannabis products in Canada;
The Company’s Research & Development program, in collaboration with strategic partners, have developed patentable intellectual properties for filing in the current fiscal year ending February 28, 2024.